Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

BIRMINGHAM, Ala., Oct. 31 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter ended September 30, 2008.

Third Quarter 2008 Financial Results

For the three months ended September 30, 2008, the Company reported collaborative and other research and development revenues of $8.9 million compared to $20.5 million for the three months ended September 30, 2007. This decrease is driven by a reduction in peramivir clinical development costs and associated revenue from the contract with the U.S. Department of Health and Human Services (HHS) for the development of peramivir. Currently, the majority of the Company's revenues are derived from the reimbursement of costs under the contract with HHS.

Research and development (R&D) expenses were $16.0 million for the three months ended September 30, 2008, compared to $29.7 million for the three months ended September 30, 2007. The decrease in R&D expenses is primarily attributable to a reduction in clinical development costs associated with the peramivir program, a reduction in manufacturing costs associated with both the peramivir and forodesine HCl program and a reduction in costs incurred related to the Company's preclinical programs. These reductions were partially offset by an increase in BioCryst's clinical development costs in the forodesine HCl program.

General and administrative (G&A) expenses were $2.5 million for the three months ended September 30, 2008, compared to $2.6 million for the three months ended September 30, 2007.

The net loss for the quarter ended September 30, 2008 was $9.0 million, or $0.24 per share, compared to a net loss for the quarter ended September 30, 2007 of $11.0 mill
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... Oral Amphotericin B program.  The company recently announced ... work involving samples from HIV/AIDS patients exposed to ... clinical studies and regulatory filings to move forward ... approximately $700,000 of funding and technological advice from ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
(Date:10/20/2014)... , October 20, 2014 , ... (GI) disorders and the delivery of care has revealed ... and worrying inequalities in the provision of healthcare services ... was commissioned by United European Gastroenterology (UEG), have been ... and public awareness of the burden of GI disorders ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... Corp. Ltd., a developer and marketer of innovative products ... today announced that Gary Levine has been appointed Chief ... has joined the company as Director of Reagents Development ... Martin, ZyGEM is developing an innovative Rapid DNA analysis ...
... have created a working cloaking device that not only ... but also boasts unique features; it has an ,on ... The researchers, from the University of Dallas, Texas, ... in a fascinating video shown here http://www.youtube.com/watch?v=3YO4TTpYg7g ...
... Agendia, an innovative molecular cancer diagnostics company, ... routine inspection of its Irvine, California-based laboratories by the ... 510(k) clearance for its MammaPrint® breast cancer recurrence test ... test of its kind to receive FDA clearance, which, ...
Cached Biology Technology:ZyGEM Strengthens Senior Management Team With New Appointments 2ZyGEM Strengthens Senior Management Team With New Appointments 3'Mirage-effect' helps researchers hide objects 2Agendia Successfully Completes Bi-Annual FDA Inspection 2
(Date:10/15/2014)... admitted Johannes Gutenberg University Mainz (JGU) as a ... continues to maintain a significant nationwide standing in ... acceptance of Johannes Gutenberg University Mainz as a ... in the national and international competition for the ... Rhineland-Palatinate can be proud that Mainz University has ...
(Date:10/15/2014)... Conn. , Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce market releases ... MarketSite in Times Square on Monday October 13 th . ... CTO David Tunnel and angel investor Mr. Chad ... Pereira , CEO of NXT-ID thanked his investors and employees "for ...
(Date:10/14/2014)... – Like discriminating thieves, prostate cancer tumors scavenge and ... body. But such avarice may be a fatal weakness. ... way to kill prostate cancer cells by delivering a ... destroys the diseased cells brimming with the mineral, leaving ... two drugs already commercially available for other uses, could ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... platform, complete with biometric enrollment, authentication, data ... formatting, and background check connectivity, BEDFORD, ... (Nasdaq: AWRE ), a global provider of biometrics ... with Sun identity management solutions. The integration of,BioSP with ...
... Natural selection . . . By examining ... Oak Ridge National Laboratory hope to develop a strategy ... a process known as association mapping, scientists will attempt ... growing in natural populations with the goal being to ...
... research team in Antarctica led by David Marchant, ... University, has reported the discovery of exceptionally well-preserved ... as diatoms, small fresh water crustaceans, and insects ... the southernmost region of the continent before a ...
Cached Biology News:Sun Microsystems and Aware, Inc. Announce Integration of Aware's BioSP with Sun Identity Management Solutions 2Sun Microsystems and Aware, Inc. Announce Integration of Aware's BioSP with Sun Identity Management Solutions 3Sun Microsystems and Aware, Inc. Announce Integration of Aware's BioSP with Sun Identity Management Solutions 4Sun Microsystems and Aware, Inc. Announce Integration of Aware's BioSP with Sun Identity Management Solutions 5Story tips from the US Department of Energy's Oak Ridge National Laboratory, August 2008 2Story tips from the US Department of Energy's Oak Ridge National Laboratory, August 2008 3Rare Antarctic fossils reveal extinction of tundra before full polar climate arrived 2Rare Antarctic fossils reveal extinction of tundra before full polar climate arrived 3
... GenePix Professional 4200A can be upgraded to ... automatically loads, scans, analyzes, and saves results ... you by email when the batch is ... even for warped slides. GenePix Pro gives ...
... the value of your microarray data using ... you need from consultation to extensive data ... methods. Utilize our expertise in combination with ... your own microarray experiments., ,Normalization and basic ...
... Maximize the value of your ... We offer the support you need ... using the most up to date ... with the Gene Expression Profiling Service ...
... This CLS number is a ... easily match Cornings product number. ... please order under the old ... customer service for assistance. ...
Biology Products: